SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community
 
| More

TMCNet:  U.S. Patents Awarded to Inventors in California (Dec. 29)

[December 29, 2012]

U.S. Patents Awarded to Inventors in California (Dec. 29)

(Targeted News Service Via Acquire Media NewsEdge) Targeted News Service Targeted News Service ALEXANDRIA, Va., Dec. 29 -- The following federal patents were awarded to inventors in California.

*** Alcon Research Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Alcon Research, Fort Worth, Texas, has been assigned a patent (8,337,453) developed by Casey Jean Lind, Irvine, Calif., for a "drug pellet molding onto plunger assembly." The abstract of the patent published by the U.S. Patent and Trademark Office states: "A pellet loading apparatus has a pellet housing configured to receive and hold a plunger so that a cavity is formed by an interior surface of the pellet housing and the plunger. A pellet is located or formed in the cavity. A dispensing chamber housing is located in a disposable drug delivery device. The dispensing chamber housing is configured to couple with the pellet housing so that the plunger and the pellet can be loaded into the dispensing chamber housing." The patent application was filed on Dec. 3, 2008 (12/327,020). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,453&OS=8,337,453&RS=8,337,453 Written by Neha Bharti; edited by Jaya Anand.



*** Dart Neuroscience Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Dart Neuroscience, San Diego, has been assigned a patent (8,338,405) developed by Terence P. Keenan, San Diego, and Alan P. Kaplan, San Diego, for therapeutic piperazines.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention includes a compound of formula I: ##STR00001## wherein R.sub.1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in animals." The patent application was filed on Aug. 23, 2010 (12/861,213). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,405&OS=8,338,405&RS=8,338,405 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Medivation Technologies Assigned Patent for Pyrido[3,4-B]Indoles and Methods of Use ALEXANDRIA, Va., Dec. 29 -- Medivation Technologies, San Francisco, has been assigned a patent (8,338,447) developed by five co-inventors for "pyrido[3,4-B]indoles and methods of use." The co-inventors are David T. Hung, Redwood City, Calif., Andrew Asher Protter, Palo Alto, Calif., Sarvajit Chakravarty, Mountain View, Calif., Rajendra P. Jain, Maharashtra, India, and Sundeep Dugar, San Jose, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds of formula (I) ##STR00001## are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder." The patent application was filed on March 24, 2009 (12/410,407). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,447&OS=8,338,447&RS=8,338,447 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Amgen Assigned Patent for Compounds and Methods of Use ALEXANDRIA, Va., Dec. 29 -- Amgen, Thousand Oaks, Calif., has been assigned a patent (8,338,455) developed by four co-inventors for "compounds and methods of use." The co-inventors are Yuan Cheng, Newbury Park, Calif., Deborah Choquette, Medford, Mass., Jean-Christophe Harmange, Andover, Mass., and Andrew Tasker, Simi Valley, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Selected compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes." The patent application was filed on Dec. 19, 2007 (12/004,156). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,455&OS=8,338,455&RS=8,338,455 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Medicinova Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Medicinova, San Diego, has been assigned a patent (8,338,453) developed by four co-inventors for a "treatment of progressive neurodegenerative disease with ibudilast." The co-inventors are Michael E. Kalafer, La Jolla, Calif., Kenneth W. Locke, Carlsbad, Calif., Kazuko Matsuda, Beverly Hills, Calif., and Richard E. Gammans, Vass, N.C.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2 -isopropylpyrazolo[1,5-a]pyridine)." The patent application was filed on Feb. 22, 2012 (13/402,702). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,453&OS=8,338,453&RS=8,338,453 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Strix Systems Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Strix Systems, Westlake Village, Calif., has been assigned a patent (8,340,024) developed by five co-inventors for a "virtual linking using a wireless device." The co-inventors are Spencer Stephens, Toluca Lake, Calif., Duke Kamstra, Thousand Oaks, Calif., James M. Jollota, Simi Valley, Calif., James Fuhring, Ventura, Calif., and James Beasley, Simi Valley, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A system and method for virtual linking a wireless device to another device is disclosed herein. The system includes an access point and a controller configured to mediate transmissions between the wireless device and the another device. The system further includes a virtual device table and a permissions filter to ensure virtual linking between devices that have matching access right and requested services. The wireless device and the another device may have the same or dissimilar protocols." The patent application was filed on Feb. 17, 2010 (12/706,969). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,340,024&OS=8,340,024&RS=8,340,024 Written by Neha Bharti; edited by Jaya Anand.

*** Adamas Pharmaceuticals Assigned Patent for Compositions for the Treatment of CNS-related Conditions ALEXANDRIA, Va., Dec. 29 -- Adamas Pharmaceuticals, Emeryville, Calif., has been assigned a patent (8,338,485) developed by Gregory T. Went, Mill Valley, Calif., Timothy J. Fultz, Pleasant Hill, Calif., and Laurence R. Meyerson, Las Vegas, for "compositions for the treatment of CNS-related conditions." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration." The patent application was filed on June 28, 2012 (13/536,588). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,485&OS=8,338,485&RS=8,338,485 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Valeant Pharmaceuticals International Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Valeant Pharmaceuticals International, Aliso Viejo, Calif., has been assigned a patent (8,338,487) developed by Huanming Chen, Irvine, Calif., and Jean-Michel Vernier, Laguna Niguel, Calif., for "substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1H-indenes as potassium channel modulators." The abstract of the patent published by the U.S. Patent and Trademark Office states: "This invention provides compounds of formula I ##STR00001## where Ar.sub.1 is a 5- to 10-member mono- or bicyclic aromatic group, optionally substituted; where the --NR.sub.3R.sub.4 group is situated ortho to the NHC(.dbd.X) group; n=1 or 2; X=O or S; Y is O or S; and q=1 or 0. The invention also provides pharmaceutical compositions comprising compounds of formula I and/or salts, esters, and prodrugs thereof. These compounds modulate the activation and inactivation of potassium channels. The compounds are useful for the treatment and prevention of diseases and disorders--such as seizure disorders--which are affected by modulation of potassium ion channels." The patent application was filed on April 29, 2011 (13/098,176). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,487&OS=8,338,487&RS=8,338,487 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Hospira Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Hospira, Lake Forest, Ill., has been assigned a patent (8,338,470) developed by Priyanka Roychowdhury, San Rafael, Calif., and Robert A. Cedergren, Libertyville, Ill., for a dexmedetomidine premix formulation.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation." The patent application was filed on July 3, 2012 (13/541,524). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,470&OS=8,338,470&RS=8,338,470 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Adamas Pharmaceuticals Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Adamas Pharmaceuticals, Emeryville, Calif., has been assigned a patent (8,338,486) developed by Gregory T. Went, Mill Valley, Calif., Timothy J. Fultz, Pleasant Hill, Calif., and Laurence R. Meyerson, Las Vegas, for "methods for the treatment of CNS-related conditions." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration." The patent application was filed on June 28, 2012 (13/536,763). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,486&OS=8,338,486&RS=8,338,486 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Panmira Pharmaceuticals Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Panmira Pharmaceuticals, San Diego, has been assigned a patent (8,338,484) developed by John Howard Hutchinson, La Jolla, Calif., Brian Andrew Stearns, San Diego, and Yen Pham Truong, San Diego, for "N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Described herein are compounds that are antagonists of PGD.sub.2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD.sub.2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD.sub.2-dependent or PGD.sub.2-mediated conditions or diseases." The patent application was filed on Nov. 15, 2011 (13/297,160). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,484&OS=8,338,484&RS=8,338,484 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Allergan Assigned Patent for Enhanced Bimatoprost Ophthalmic Solution ALEXANDRIA, Va., Dec. 29 -- Allergan, Irvine, Calif., has been assigned a patent (8,338,479) developed by five co-inventors for an "enhanced bimatoprost ophthalmic solution." The co-inventors are Chin-Ming Chang, Tustin, Calif., James N. Chang, Newport Beach, Calif., Rhett M. Schiffman, Laguna Beach, Calif., R. Scott Jordan, Trabuco Canyon, Calif., and Joan-En Chang-Lin, Tustin, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein." The patent application was filed on Jan. 9, 2009 (12/351,383). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,479&OS=8,338,479&RS=8,338,479 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Stanford University Assigned Patent for Derivation of Neural Stem Cells from Embryonic Stem Cells ALEXANDRIA, Va., Dec. 29 -- Stanford University, Palo Alto, Calif., has been assigned a patent (8,338,176) developed by Marcel M. Daadi, Palo Alto, Calif., and Gary K. Steinberg, Redwood City, Calif., for "derivation of neural stem cells from embryonic stem cells." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease." The patent application was filed on July 29, 2008 (12/182,050). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,176&OS=8,338,176&RS=8,338,176 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Medivation Technologies Assigned Patent for Tetracyclic Compounds ALEXANDRIA, Va., Dec. 29 -- Medivation Technologies, San Francisco, has been assigned a patent (8,338,408) developed by 11 co-inventors for tetracyclic compounds. The co-inventors are David T. Hung, Redwood City, Calif., Andrew A. Protter, Palo Alto, Calif., Rajendra P. Jain, Maharashtra, India, Sundeep Dugar, San Jose, Calif., Sarvajit Chakravarty, Mountain View, Calif., Sergey O. Bachurin, Chernogolovka, Russia, Anatoly K. Ustinov, Chernogolovka, Russia, Bogdan K. Beznosko, Chernogolovka, Russia, Nadezhda Sergeevna Beznosko legal representative, Chernogolovka, Russia, Elena F. Shevtsova, Chernogolovka, Russia, and Vladimir V. Grigoriev, Chernogolovka, Russia.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder." The patent application was filed on Oct. 27, 2008 (12/259,234). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,408&OS=8,338,408&RS=8,338,408 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** OmniVision Technologies Assigned Patent ALEXANDRIA, Va., Dec. 29 -- OmniVision Technologies, Santa Clara, Calif., has been assigned a patent (8,338,263) developed by Chia-Ying Liu, Hsinchu, Taiwan, Keh-Chiang Ku, Cupertino, Calif., and Wu-Zhang Yang, Chuang-Huang County, Taiwan, for an "etching narrow, tall dielectric isolation structures from a dielectric layer." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Methods of forming isolation structures are disclosed. A method of forming isolation structures for an image sensor array of one aspect may include forming a dielectric layer over a semiconductor substrate. Narrow, tall dielectric isolation structures may be formed from the dielectric layer. The narrow, tall dielectric isolation structures may have a width that is no more than 0.3 micrometers and a height that is at least 1.5 micrometers. A semiconductor material may be epitaxially grown around the narrow, tall dielectric isolation structures. Other methods and apparatus are also disclosed." The patent application was filed on June 20, 2011 (13/164,619). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,263&OS=8,338,263&RS=8,338,263 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Alpha & Omega Semiconductor Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Alpha & Omega Semiconductor, Sunnyvale, Calif., has been assigned a patent (8,338,232) developed by Lei Shi, Shanghai, China, Yan Xun Xue, Los Gatos, Calif., and Yuping Gong, Shanghai, China, for a "power semiconductor device package method." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Preparation methods of forming packaged semiconductor device, specifically for flip-chip vertical power device, are disclosed. In these methods, a vertical semiconductor chip is flip-chip attached to a lead frame and then encapsulated with plastic packing materials. Encapsulated chip is then thinned to a predetermined thickness. Contact terminals connecting the chip with external circuit are formed by etching at least a bottom portion of the lead frame connected." The patent application was filed on March 10, 2011 (13/045,407). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,232&OS=8,338,232&RS=8,338,232 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Quarkstar Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Quarkstar, Las Vegas, has been assigned a patent (8,338,199) developed by five co-inventors for a "solid state light sheet for general illumination." The co-inventors are Louis Lerman, Las Vegas, Allan Brent York, Langley, Calif., Michael David Henry, Albuquerque, N.M., Robert Steele, Redwood City, Calif., and Brian D. Ogonowsky, Mountain View, Calif..

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A solid state light sheet and method of fabricating the sheet are disclosed. In one embodiment, bare blue-light LED chips have top and bottom electrodes, where the bottom electrode is a large reflective electrode.The bottom electrodes of an array of LEDs (e.g., 500 LEDs) are bonded to an array of electrodes formed on a flexible bottom substrate. Conductive traces are formed on the bottom substrate connected to the electrodes. In one embodiment, an intermediate sheet having holes is then affixed to the bottom substrate, with the LEDs passing through the holes. A transparent top substrate having conductors is then laminated over the intermediate sheet. In another embodiment, no intermediate sheet is used. Various ways to connect the LEDs in series are described along with many embodiments. The light sheet provides a practical substitute for a standard 2.times.4 foot fluorescent ceiling fixture. A phosphor is used to generate white light." The patent application was filed on Aug. 27, 2010 (12/870,760). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,199&OS=8,338,199&RS=8,338,199 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Theravance Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Theravance, South San Francisco, Calif., has been assigned a patent (8,338,424) developed by four co-inventors for "guanidine-containing compounds useful as muscarinic receptor antagonists." The co-inventors are YuHua Ji, Redwood City, Calif., Craig Husfeld, Redwood City, Calif., YongQi Mu, Los Altos, Calif., Rick Lee, Daly City, Calif., and Li Li, Sunnyvale, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention provides compounds of formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.1-3, R.sup.5-7, a, X, Y, Y', Y'', and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma." The patent application was filed on May 10, 2012 (13/468,200). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,424&OS=8,338,424&RS=8,338,424 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Pharmacylics Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Pharmacylics, Sunnyvale, Calif., has been assigned a patent (8,338,416) developed by five co-inventors for "indole derivatives as inhibitors of histone deacetylase." The co-inventors are Joseph J. Buggy, Mountain View, Calif., Sriram Balasubramanian, San Carlos, Calif., Erik Verner, San Mateo, Calif., Vincent W.F. Tai, San Mateo, Calif., and Chang-Sun Lee, Belle Mead, N.J.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity." The patent application was filed on March 16, 2007 (11/687,565). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,416&OS=8,338,416&RS=8,338,416 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Twin Creeks Technologies Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Twin Creeks Technologies, San Jose, Calif., has been assigned a patent (8,338,209) developed by Mohamed M. Hilali, Sunnyvale, Calif., and Christopher J. Petti, Mountain View, Calif., for a "photovoltaic cell comprising a thin lamina having a rear junction and method of making." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Fabrication of a photovoltaic cell comprising a thin semiconductor lamina may require additional processing after the semiconductor lamina is bonded to a receiver. To minimize high-temperature steps after bonding, the p-n junction is formed at the back of the cell, at the bonded surface. In some embodiments, the front surface of the semiconductor lamina is not doped or is locally doped using low-temperature methods. The base resistivity of the photovoltaic cell may be reduced, allowing a front surface field to be reduced or omitted." The patent application was filed on Aug. 10, 2008 (12/189,158). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,209&OS=8,338,209&RS=8,338,209 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Viacyte Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Viacyte, San Diego, has been assigned a patent (8,338,170) developed by Olivia Kelly, San Diego, and Anne Bang, San Diego, for "methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells." The patent application was filed on April 21, 2008 (12/107,020). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,170&OS=8,338,170&RS=8,338,170 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Allergan Assigned Patent for Substituted 3-(5-membered Unsaturated Heterocyclyl-1, 3-dihydro-indol-2-one's and Derivatives Thereof as Kinase Inhibitors ALEXANDRIA, Va., Dec. 29 -- Allergan, Irvine, Calif., has been assigned a patent (8,338,415) developed by four co-inventors for a "substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors." The co-inventors are Xialing Guo, San Clemente, Calif., Zhen Zhu, Foothill Ranch, Calif., Thomas C. Malone, Irvine, Calif., and Julie Wurster, Irvine, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention relates to a compound of Formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, as disclosed herein. The present invention also relates to pharmaceutical compositions comprising said compounds and to methods of using said compounds and compositions for modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation." The patent application was filed on Jan. 23, 2007 (11/625,856). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,415&OS=8,338,415&RS=8,338,415 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Pharmacia Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Pharmacia, St. Louis, has been assigned a patent (8,338,374) developed by Manpreet S. Wadhwa, Thousand Oaks, Calif., Sandeep Nema, St. Louis, and Advait Badkar, Wildwood, Mo., for a "stable growth hormone liquid formulation." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone)." The patent application was filed on Dec. 13, 2004 (10/583,923). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,374&OS=8,338,374&RS=8,338,374 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Applied Materials Assigned Patent for Negatively Charged Passivation Layer in a Photovoltaic Cell ALEXANDRIA, Va., Dec. 29 -- Applied Materials, Santa Clara, Calif., has been assigned a patent (8,338,220) developed by Peter G. Borden, San Mateo, Calif., and Christopher Sean Olsen, Fremont, Calif., for a "negatively charged passivation layer in a photovoltaic cell." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Embodiments of the invention are directed to methods and apparatus for processing of a solar substrate for making a photovoltaic device. In particular, methods and apparatus for creating a negatively charged passivation layer by are provided." The patent application was filed on Feb. 6, 2009 (12/367,064). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,220&OS=8,338,220&RS=8,338,220 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Allergan Assigned Patent for Packaged Product ALEXANDRIA, Va., Dec. 29 -- Allergan, Irvine, Calif., has been assigned a patent (8,338,375) developed by Jacqueline Anne Schroeder, Boulder Creek, Calif., Gregory S. Dapper, Newark, Calif., and Kenneth C. Olson, Foster City, Calif., for a packaged product.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft tissues in mammals." The patent application was filed on Dec. 29, 2009 (12/649,020). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,375&OS=8,338,375&RS=8,338,375 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** MiaSole Assigned Patent ALEXANDRIA, Va., Dec. 29 -- MiaSole, Santa Clara, Calif., has been assigned a patent (8,338,214) developed by four co-inventors for a "sodium salt containing CIG targets, methods of making and methods of use thereof." The co-inventors are Daniel R. Juliano, Santa Clara, Calif., Robert Tas, Aromas, Calif., Neil Mackie, Fremont, Calif., and Abdelouahab Ziani, Santa Clara, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A sputtering target includes at least one metal selected from copper, indium and gallium and a sodium containing compound." The patent application was filed on March 28, 2011 (13/073,159). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,214&OS=8,338,214&RS=8,338,214 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** University of Southern California Assigned Patent ALEXANDRIA, Va., Dec. 29 -- The University of Southern California, Los Angeles, has been assigned a patent (8,338,365) developed by Radu O. Minea, Arcadia, Calif., and Francis S. Markland Jr., Manhattan Beach, Calif., for an "inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains." The abstract of the patent published by the U.S. Patent and Trademark Office states: "This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of .alpha.IIb.beta.3, .alpha.v.beta.3, .alpha.v.beta.5, or .alpha.5.beta.1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop." The patent application was filed on Feb. 6, 2012 (13/367,267). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,365&OS=8,338,365&RS=8,338,365 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Clinical Decision Support Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Clinical Decision Support, Nashville, Tenn., has been assigned a patent (8,337,409) developed by Edwin C. Iliff, La Jolla, Calif., for "computerized medical diagnostic system utilizing list-based processing." The abstract of the patent published by the U.S. Patent and Trademark Office states: "A system and method for providing computerized, knowledge-based medical diagnostic advice. The medical advice is provided to the general public over a network, such as a telephone network with the use of a telephone or the Internet with the use of an Internet access device. Alternatively, the medical advice can be provided to a patient in a stand-alone mode by use of a computer. The invention utilizes a list-based processing method of generating and executing diagnostic scripts. For the purpose of diagnosing a health problem of a patient, medical knowledge is organized into a list of the diseases to be considered. Each disease on the disease list includes a list of symptoms that is checked in a patient. Each symptom on the symptom list is then further described as a response to a list of one or more questions asked of the patient about the symptom. This triply-nested list structure is converted by suitable data structure transformations into a script that is stored. When a patient requires diagnosis, the script is played back as a sequence of questions. The responses of the patient are analyzed and converted into symptoms. The symptoms are accumulated into diseases. Finally the diseases are selected and reported as a diagnosis." The patent application was filed on Oct. 31, 2007 (11/932,190). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,409&OS=8,337,409&RS=8,337,409 Written by Neha Bharti; edited by Jaya Anand.

*** Illumina Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Illumina, San Diego, has been assigned a patent (8,338,187) developed by Chad F. DeRosie, San Diego, for "methods and systems for controlling liquids in multiplex assays." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Methods and systems for venting a well that receives a liquid. The method includes providing a microplate including a well that has a cavity with an open inlet and a closed end. The cavity extends between the open inlet and the closed end. The cavity is defined by a wall surface having a cross-sectional contour that includes at least one continuous section and at least one discontinuity section. The method also includes depositing a liquid into the open inlet of the well. The liquid enters the cavity and flows toward the closed end to at least partially fill the well. The liquid flows along the continuous section of the wall surface and remains separated from the discontinuity section of the wall surface, thereby maintaining a gas exhaust path along a spacing between the liquid and the discontinuity section as the liquid flows toward the closed end." The patent application was filed on Feb. 23, 2010 (13/143,027). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,187&OS=8,338,187&RS=8,338,187 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** University of Southern California Assigned Patent ALEXANDRIA, Va., Dec. 29 -- The University of Southern California, Los Angeles, has been assigned a patent (8,337,444) developed by Eduardo H. Rubinstein, Los Angeles, Daniel P. Holschneider, Los Angeles, and Jean-Michel I. Maarek, Rancho Palos Verdes, Calif., for "measurement of cardiac output and blood volume by non-invasive detection of indicator dilution for hemodialysis." The abstract of the patent published by the U.S. Patent and Trademark Office states: "A system and method of non-invasive or minimally invasive evaluating the cardiovascular system parameters to estimate the cardiac output and circulating blood volume of a patient undergoing hemodialysis. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health before and during hemodialysis." The patent application was filed on May 3, 2007 (11/744,157). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,444&OS=8,337,444&RS=8,337,444 Written by Neha Bharti; edited by Jaya Anand.

*** Gilead Sciences Assigned Patent for Substituted Pyrido(3,2-D) Pyrimidines and Pharmaceutical Compositions for Treating Viral Infections ALEXANDRIA, Va., Dec. 29 -- Gilead Sciences, Foster City, Calif., has been assigned a patent (8,338,435) developed by five co-inventors for "substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections." The co-inventors are Piet Andre Maurits Maria Herdewijn, Rotselaar/Wezemaal, Belgium, Steven Cesar Alfons De Jonghe, Brussels, Belgium, William John Watkins, Saratoga, Calif., Lee Shun Chong, Newark, Calif., and Jennifer Zhang, Foster City, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic conditions associated therewith, including hepatitis C. ##STR00001##" The patent application was filed on June 20, 2007 (12/374,223). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,435&OS=8,338,435&RS=8,338,435 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** J. David Gladstone Institutes Assigned Patent ALEXANDRIA, Va., Dec. 29 -- J. David Gladstone Institutes, San Francisco, has been assigned a patent (8,338,180) developed by four co-inventors for "methods for treating lentivirus infections." The co-inventors are Warner C. Greene, Hillsborough, Calif., Kimberly S. Stopak, San Francisco, Carlos M.C. deNoronha, Slingerlands, N.Y., and Wesley M. Yonemoto, San Francisco.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. The present invention provides agents identified by a subject screening method; and further provides methods for treating lentivirus infections." The patent application was filed on June 9, 2004 (10/865,663). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,180&OS=8,338,180&RS=8,338,180 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Nu Vasive Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Nu Vasive, San Diego, has been assigned a patent (8,337,410) developed by five co-inventors for electromyography system. The co-inventors are Brian S. Kelleher, Ramona, Calif., James F. Marino, La Jolla, Calif., Corbett W. Stone, San Diego, Robin H. Vaughn, Escondido, Calif., and Jeffrey H. Owens, Monkton, Md.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Methods for determining structural integrity of a bone within the spine of a patient, the bone having a first aspect and a second aspect, wherein the second aspect separated from the first aspect by a width and located adjacent to a spinal nerve. The methods involve (a) applying an electrical stimulus to the first aspect of the bone; (b) electrically monitoring a muscle myotome associated with the spinal nerve to detect if an onset neuro-muscular response occurs in response to the application of the electrical stimulus to the first aspect of the bone; (c) automatically increasing the magnitude of the electrical stimulus to until the onset neuro-muscular response is detected; and (d) communicating to a user via at least one of visual and audible means information representing the magnitude of the electrical stimulus which caused the onset neuro-muscular response." The patent application was filed on Aug. 2, 2011 (13/196,784). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,410&OS=8,337,410&RS=8,337,410 Written by Neha Bharti; edited by Jaya Anand.

*** Innovative Micro Technology Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Innovative Micro Technology, Goleta, Calif., has been assigned a patent (8,338,283) developed by David M. Erlach, Santa Barbara, Calif., for a "method and apparatus for applying thin liquid coatings." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Systems and methods for applying a thin layer of a liquid to the surface of a wafer with topography formed therein. The systems and methods include spreading a deposit of the liquid into a thin film on a wafer support, lowering the wafer onto the film, removing the wafer with an adhering layer of the film, positioning the wafer over a device wafer with the liquid film disposed between the wafers, curing the thin layer. The thin layer may be a UV adhesive which bonds the wafers upon exposure to UV light." The patent application was filed on Dec. 7, 2011 (13/373,969). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,283&OS=8,338,283&RS=8,338,283 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Corning Assigned Patent for Methods and Apparatus for Producing Semiconductor on Insulator Structures Using Directed Exfoliation ALEXANDRIA, Va., Dec. 29 -- Corning, Corning, N.Y., has been assigned a patent (8,338,269) developed by six co-inventors for "methods and apparatus for producing semiconductor on insulator structures using directed exfoliation." The co-inventors are Sarko Cherekdjian, Campbell, Calif., Jeffrey Scott Cites, Horseheads, N.Y., James Gregory Couillard, Ithaca, N.Y., Richard Orr Maschmeyer, Corning, N.Y., Michael John Moore, Corning, N.Y., and Alex Usenko, Painted Post, N.Y.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Methods and apparatus provide for forming a semiconductor-on-insulator (SOI) structure, including subjecting a implantation surface of a donor semiconductor wafer to an ion implantation step to create a weakened slice in cross-section defining an exfoliation layer of the donor semiconductor wafer; and subjecting the donor semiconductor wafer to a spatial variation step, either before, during or after the ion implantation step, such that at least one parameter of the weakened slice varies spatially across the weakened slice in at least one of X- and Y- axial directions." The patent application was filed on Oct. 5, 2011 (13/253,451). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,269&OS=8,338,269&RS=8,338,269 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Lawrence Livermore National Security Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Lawrence Livermore National Security, Livermore, Calif., has been assigned a patent (8,338,322) developed by four co-inventors for "transparent ceramics and methods of preparation thereof." The co-inventors are Joel P. Hollingsworth, Oakland, Calif., Joshua D. Kuntz, Livermore, Calif., Zachary M. Seeley, Pullman, Wash., and Thomas F. Soules, Livermore, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method for forming a transparent ceramic preform in one embodiment includes forming a suspension of oxide particles in a solvent, wherein the suspension includes a dispersant, with the proviso that the suspension does not include a gelling agent; and uniformly curing the suspension for forming a preform of gelled suspension. A method according to another embodiment includes creating a mixture of inorganic particles, a solvent and a dispersant, the inorganic particles having a mean diameter of less than about 2000 nm; agitating the mixture; adding the mixture to a mold; and curing the mixture in the mold for gelling the mixture, with the proviso that no gelling agent is added to the mixture." The patent application was filed on Aug. 30, 2011 (13/221,788). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,322&OS=8,338,322&RS=8,338,322 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** California Institute of Technology Assigned Patent ALEXANDRIA, Va., Dec. 29 -- California Institute of Technology, Pasadena, Calif., has been assigned a patent (8,338,387) developed by four co-inventors for "small molecule stimulators of neuronal growth." The co-inventors are Linda C. Hsieh-Wilson, San Marino, Calif., Sarah E. Tully, Pasadena, Calif., Ross Mabon, Princeton, N.J., and Cristal I. Gama, Los Angeles.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein." The patent application was filed on July 29, 2009 (12/511,944). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,387&OS=8,338,387&RS=8,338,387 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Array BioPharma, Genentech Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Array BioPharma, Boulder, Colo., and Genentech, South San Francisco, Calif., have been assigned a patent (8,338,452) developed by 16 co-inventors for "RAF inhibitor compounds and methods of use thereof." The co-inventors are Kateri A. Ahrendt, Boulder, Colo., Alexandre J. Buckmelter, Boulder, Colo., Jonas Grina, Boulder, Colo., Joshua D. Hansen, Boulder, Colo., Ellen R. Laird, Boulder, Colo., David Moreno, Boulder, Colo., Brad Newhouse, Boulder, Colo., Li Ren, Boulder, Colo., Steven M. Wenglowsky, Boulder, Colo., Bainian Feng, South San Francisco, Calif., Janet Gunzner, South San Francisco, Calif., Kim Malesky, South San Francisco, Calif., Simon Mathieu, South San Francisco, Calif., Joachim Rudolph, South San Francisco, Calif., Zhaoyang Wen, South San Francisco, Calif., and Wendy B. Young, South San Francisco, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. ##STR00001##" The patent application was filed on Feb. 27, 2009 (12/920,045). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,452&OS=8,338,452&RS=8,338,452 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Amtech Systems Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Amtech Systems, Tempe, Ariz., has been assigned a patent (8,338,211) developed by Jeong-Mo Hwang, San Jose, Calif., for "systems and methods for charging solar cell layers." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Systems and methods of the present invention can be used to charge a charge-holding layer (such as a passivation layer and/or antireflective layer) of a solar cell with a positive or negative charge as desired. The charge-holding layer(s) of such a cell can include any suitable dielectric material capable of holding either a negative or a positive charge, and can be charged at any suitable point during manufacture of the cell, including during or after deposition of the passivation layer(s). A method according to one aspect of the invention includes disposing a solar cell in electrical communication with an electrode inside a chamber. The solar cell includes an emitter, a base, a first passivation layer adjacent the emitter, and a second passivation layer adjacent the base. Gas is injected into the chamber and a plasma (with photons having an energy level of at least about 3.1 eV) is generated using the gas. One or more of the first passivation layer and the second passivation layer is charged to a predetermined polarity, wherein the charging includes applying a direct current voltage pulse to the electrode for a predetermined period of time." The patent application was filed on March 17, 2011 (13/050,915). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,211&OS=8,338,211&RS=8,338,211 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Encapsule Medical Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Encapsule Medical, San Francisco, has been assigned a patent (8,337,414) developed by five co-inventors for "methods and devices for removing tissue from a patient." The co-inventors are James W. Vetter, Portola Valley, Calif., Ary S. Chernomorsky, Walnut Creek, Calif., Christopher Daniel, Palo Alto, Calif., Mark J. Clifford, Los Altos, Calif., and Scott C. Anderson, Sunnyvale, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention is directed to tissue removal devices and methods. A tubular element having an open distal end is advanced into tissue so that tissue enters the tubular element. The tissue, which entered the tubular element is cut to separate the tissue from the surrounding tissue. The tissue is then transported proximally by the cutting element or a separate transport element." The patent application was filed on Nov. 24, 2009 (12/592,362). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,414&OS=8,337,414&RS=8,337,414 Written by Neha Bharti; edited by Jaya Anand.

*** General Atomics Assigned Patent ALEXANDRIA, Va., Dec. 29 -- General Atomics, San Diego, has been assigned a patent (8,338,184) developed by Chong-Sheng Yuan, San Diego, Abhijit Datta, Carlsbad, Calif., and Limin Liu, San Diego, for "methods for assaying percentage of glycated hemoglobin." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention." The patent application was filed on April 8, 2011 (13/083,357). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,184&OS=8,338,184&RS=8,338,184 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** National Center for Pelvic Pain Research Devices Assigned Patent ALEXANDRIA, Va., Dec. 29 -- National Center for Pelvic Pain Research Devices, Sebastopol, Calif., has been assigned a patent (8,337,435) developed by David Wise, Sebastopol, Calif., for a "method and apparatus for treating pelvic pain." The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method and apparatus for self-treating internal muscle and trigger points related to pelvic pain in women and men. The apparatus includes a rod having a handle attached to a straight portion at a first end of the rod and a pressure applicator attached to a second end of the rod, where a first curved portion is disposed between the straight portion of the rod and the second end of the rod. In the method of the present invention, a trigger point is located in the patient's pelvic floor, the patient inserts the apparatus either vaginally or rectally to allow contact of the pressure applicator of the apparatus with the pelvic floor, and pressure is applied to the trigger point using the apparatus." The patent application was filed on May 6, 2008 (12/115,807). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,435&OS=8,337,435&RS=8,337,435 Written by Neha Bharti; edited by Jaya Anand.

*** Isis Pharmaceuticals Assigned Patent for Methods of Determining Potency of Chemically-synthesized Oligonucleotides ALEXANDRIA, Va., Dec. 29 -- Isis Pharmaceuticals, Carlsbad, Calif., has been assigned a patent (8,338,185) developed by Walter F. Lima, San Diego, Timothy Vickers, Oceanside, Calif., and Stanley T. Crooke, Carlsbad, Calif., for "methods of determining potency of chemically-synthesized oligonucleotides." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2." The patent application was filed on Dec. 5, 2011 (13/311,366). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,185&OS=8,338,185&RS=8,338,185 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Applied Materials Assigned Patent for Low Temperature Process for Depositing a High Extinction Coefficient Non-peeling Optical Absorber for a Scanning Laser Surface Anneal of Implanted Dopants ALEXANDRIA, Va., Dec. 29 -- Applied Materials, Santa Clara, Calif., has been assigned a patent (8,338,316) developed by four co-inventors for a "low temperature process for depositing a high extinction coefficient non-peeling optical absorber for a scanning laser surface anneal of implanted dopants." The co-inventors are Vijay Parihar, Fremont, Calif., Christopher Dennis Bencher, San Jose, Calif., Rajesh Kanuri, Santa Clara, Calif., and Marlon E. Menezes, Mountain View, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A plasma enhanced physical vapor deposition process deposits an amorphous carbon layer on an ion-implanted wafer for use in dynamic surface annealing of the wafer with an intense line beam of a laser wavelength. The deposition process is carried out at a wafer temperature below the dopant clustering threshold temperature, and includes introducing the wafer into a chamber having a carbon-containing target overlying the wafer, and furnishing a carrier gas into the chamber. The process further includes generating a wafer bias voltage and applying target source power to the carbon-containing target sufficient to produce ion bombardment of the carbon-containing target. The wafer bias voltage is set to a level at which the amorphous carbon layer that is deposited has a desired extinction coefficient at the laser wavelength." The patent application was filed on May 19, 2011 (13/111,306). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,316&OS=8,338,316&RS=8,338,316 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Masimo Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Masimo, Irvine, Calif., has been assigned a patent (8,337,403) developed by Ammar Al-Ali, Tustin, Calif., Massi E. Kiani, Laguna Niguel, Calif., and Walter M. Weber, Laguna Hills, Calif., for "patient monitor having context-based sensitivity adjustments." The abstract of the patent published by the U.S. Patent and Trademark Office states: "An application identification sensor comprises a plurality of emitters configured to transmit light into a tissue site and a detector configured to receive the light after tissue absorption. The detector generates a signal responsive to the intensity of the light and communicates the signal to a monitor. An information element is readable by the monitor so as to identify a sensor application. The monitor presets at least one user-selectable operational parameter in response to the information element." The patent application was filed on Oct. 20, 2008 (12/254,748). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,403&OS=8,337,403&RS=8,337,403 Written by Neha Bharti; edited by Jaya Anand.

*** Glaukos Assigned Patent ALEXANDRIA, Va., Dec. 29 -- Glaukos, Laguna Hills, Calif., has been assigned a patent (8,337,445) developed by four co-inventors for "ocular implant with double anchor mechanism." The co-inventors are Hosheng Tu, Newport Coast, Calif., Gregory T. Smedley, Irvine, Calif., Barbara A. Niksch, Laguna Niguel, Calif., and David S. Haffner, Mission Viejo, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention relates generally to medical devices and methods for the treatment of ocular disorders. One method provides an implant having an inlet portion with a first anchor and an outlet portion with a second anchor. The implant is implanted in tissue of an eye such the implant conducts fluid from an anterior chamber of the eye to a physiological outflow pathway of the eye. The implanting involves positioning the first anchor adjacent eye tissue, positioning the second anchor within the physiological outflow pathway, and deploying the second anchor such that the second anchor secures the implant within the physiological outflow pathway and a distal end of the second anchor is positioned further into the physiological outflow pathway than an outlet of the outlet portion." The patent application was filed on Sept. 25, 2007 (11/860,785). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,337,445&OS=8,337,445&RS=8,337,445 Written by Neha Bharti; edited by Jaya Anand.

*** Theravance Assigned Patent for Dual-acting Antihypertensive Agents ALEXANDRIA, Va., Dec. 29 -- Theravance, South San Francisco, Calif., has been assigned a patent (8,338,418) developed by four co-inventors for dual-acting antihypertensive agents. The co-inventors are Seok-ki Choi, Ann Arbor, Mich., Paul R. Fatheree, San Francisco, Roland Gendron, San Francisco, Robert Murray McKinnell, Millbrae, Calif., and Brooke Blair, San Francisco.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "In one aspect, the invention relates to compounds having the formula: ##STR00001## wherein: Ar, r, Z, X, R.sup.3, and R.sup.5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT.sub.1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds." The patent application was filed on Nov. 17, 2011 (13/298,493). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,338,418&OS=8,338,418&RS=8,338,418 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Lawrence Livermore National Security Assigned Patent for Sorting, Amplification, Detection, and Identification of Nucleic Acid Subsequences in a Complex Mixture ALEXANDRIA, Va., Dec. 29 -- Lawrence Livermore National Security, Livermore, Calif., has been assigned a patent (8,338,166) developed by four co-inventors for a "sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture." The co-inventors are Neil R. Beer, Pleasanton, Calif., Benjamin J. Hindson, Livermore, Calif., Billy W. Colson Jr., San Ramon, Calif., and Joseph P. Fitch, Livermore, Calif.

The abstract of the patent published by the U.S. Patent and Trademark Office states For more information about Targeted News Service products and services, please contact: Myron Struck, editor, Targeted News Service LLC, Springfield, Va., 703/304-1897; editor@targetednews.com; http://targetednews.com.

-1109559 (c) 2012 Targeted News Service

[ Back To LatinAmerica.tmcnet.com's Homepage 's Homepage ]

comments powered by Disqus




Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.